$2.65 Billion is the total value of RTW INVESTMENTS, LP's 61 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IMVT | New | Immunovant Inc | $66,048,000 | – | 4,426,106 | +100.0% | 2.49% | – |
| RLMD | New | Relmada Therapeutics Inc | $25,915,000 | – | 664,484 | +100.0% | 0.98% | – |
| AVDL | New | Avadel Pharmaceuticals plcsponsored adr | $25,681,000 | – | 3,401,434 | +100.0% | 0.97% | – |
| FREQ | New | Frequency Therapeutics Inc | $21,762,000 | – | 1,302,862 | +100.0% | 0.82% | – |
| NSTG | New | NanoString Technologies Inc | $16,106,000 | – | 578,932 | +100.0% | 0.61% | – |
| TELA | New | Tela Bio Inc | $14,755,000 | – | 1,139,358 | +100.0% | 0.56% | – |
| WVE | New | WAVE Life Sciences Ltd | $13,669,000 | – | 1,705,474 | +100.0% | 0.52% | – |
| A | New | Agilent Technologies Inc | $12,770,000 | – | 149,690 | +100.0% | 0.48% | – |
| STAA | New | STAAR Surgical Co | $10,629,000 | – | 302,211 | +100.0% | 0.40% | – |
| PHGE | New | Biomx Inc | $5,811,000 | – | 600,000 | +100.0% | 0.22% | – |
| FLGT | New | Fulgent Genetics Inc | $968,000 | – | 75,000 | +100.0% | 0.04% | – |
| VRAY | New | Viewray Inc | $633,000 | – | 150,000 | +100.0% | 0.02% | – |
| PHGEWS | New | BIOMX Inc*w exp 10/16/202 | $288,000 | – | 600,000 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.